My proposal now is to test a vaccine first on people who have been infected, and if you show some efficacy at this level, you might be able to go further to study uninfected people in a population with a high rate of infection.

My proposal now is to test a vaccine first on people who have been infected, and if you show some efficacy at this level, you might be able to go further to study uninfected people in a population with a high rate of infection.

The center will be fully operational in two years' time, but probably in the middle of the year we will have a temporary laboratory of 4,000 square feet.

Basic research is very useful, but it should be more geared toward application than it was before.

Our goal is not to completely eradicate the infection - that would be very difficult - but to produce a vaccine that will prevent not infection but disease. I think this is more possible.

The idea of the live-virus vaccine is to produce in a continuous way some viral antigens.

That is why it is so important not only to have excellent treatment but also to try to get back the immune defense, because there you have a natural defense that takes place everywhere.